Novartis has five fast-growing drugs, but is its valuation asking too much?
FROM THE WIRE · FINANCE.YAHOO.COM
Novartis AG (NYSE:NVS) is selling more of its newer medicines, but shareholders have yet to see the full financial benefit. In the second quarter, higher volumes contributed 18 percentage points to revenue growth. Generic competition wiped out 14 points, while lower prices…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralNovartis core sales grow little due to generic competition, so valuation remains central for investors.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01In the second quarter, higher volumes added 18 percentage points to revenue growth.
- 02Generic competition wiped out 14 points and lower prices erased another 3.
- 03Net sales grew 1% at constant currencies, with a forward P/E of about 14.71.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets